This move is archived. Current quotes and coverage live on the stock page.
Follow IMVT
Immunovant's stock faced a significant drop following disappointing trial results.
Immunovant Inc (NASDAQ:IMVT) experienced a sharp decline in its stock price, falling 7.37% in yesterday's trading session. The drop was primarily driven by the company's decision to halt the development of its lead drug candidate, imeroprubart, after it failed to meet key trial endpoints.
Investor takeaway: Investors reacted negatively to Immunovant's halted drug development, reflecting concerns over the company's future prospects in the competitive biotech landscape.
Immunovant Inc
IMVT.US
IMVT.US
Immunovant Inc
WealthAwesomeMarket cap
$6.03B
52W high
$45.42
52W low
$21.43
1W change
+0.85%
Beta
0.84
Analyst Price Targets
Based on 17 analysts covering IMVT · as of Oct 5, 2026
Wall Street analysts forecast IMVT stock price to rise 72.0% over the next 12 months.
Consensus
Buy4.41 / 5.00
Avg. Target
C$48.88
+72.0% Upside
Current Price
C$28.41
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IMVT's historical volatility
30-Day Vol
39.7%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$23.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$26.77 | C$23.34 – C$30.70 |
| 60 trading days | C$25.22 | C$20.78 – C$30.61 |
| 90 trading days | C$23.76 | C$18.74 – C$30.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Immunovant is still committed to advancing other autoimmune therapies, which could help it recover, especially if future trials show positive results.
Bear case
The failure of imeroprubart in a critical trial raises doubts about Immunovant's pipeline and its ability to deliver effective treatments, which could lead to further declines in stock value.
Disappointing Trial Results
Immunovant's recent proof-of-concept study for imeroprubart in treating cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. As a result, the company decided to cease development of the drug in this indication, which significantly impacted investor confidence.
Market Reaction and Future Outlook
The halt in drug development led to a notable sell-off, with shares closing at CA$34.54. Investors are now left to ponder the implications of this setback on Immunovant's broader pipeline and its ability to deliver future treatments. The company has indicated it will continue pursuing other autoimmune disease targets, but the market's reaction suggests skepticism about these efforts.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
